Are you asking about the MajesTEC-7 clinical trial?
MajesTEC-7 is a study evaluating teclistamab, a bispecific T-cell engager therapy, for people with relapsed or refractory multiple myeloma. This treatment works by helping your immune system's T cells recognize and attack myeloma cells.
In the trial, teclistamab showed Show Full Answer
Are you asking about the MajesTEC-7 clinical trial?
MajesTEC-7 is a study evaluating teclistamab, a bispecific T-cell engager therapy, for people with relapsed or refractory multiple myeloma. This treatment works by helping your immune system's T cells recognize and attack myeloma cells.
In the trial, teclistamab showed promising results. About 40 percent of participants experienced complete remission, meaning they had no remaining signs of myeloma after using this drug.
Teclistamab has since received FDA approval for treating relapsed or refractory multiple myeloma. It's administered through injections and represents an important new option for people whose myeloma has returned or stopped responding to other treatments.
If you're interested in whether teclistamab might be right for you, your oncology specialist can discuss your eligibility and help you understand how it fits into your treatment plan.
December 20, 2025
Join
Your Privacy Choices
